BiDil for Heart Failure in Black Patients: The U.S. Food and Drug Administration Perspective
The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
Critics of the U.S. Food and Drug Administration (FDA) approval of the fixed combination of hydralazine hydrochloride, 37.5 mg, and isosorbide dinitrate, 20 mg, for treating heart failure in black patients have suggested that data were insufficient to distinguish treatment effects in black and white people; that distinctions based on race, rather than pathophysiology, were scientifically unreasonable; and that a "race-based" approval could be a commercial ploy to avoid a more expensive and prolonged full evaluation of a drug. The criticisms acknowledge that data supporting the approval came from a well-designed clinical trial in which self-identified black patients with heart failure who took hydralazine hydrochloride-isosorbide dinitrate with standard therapy experienced a statistically significant 43% (95% CI, 11% to 63%) reduction in mortality compared with those who took only the standard therapy. The criticisms do not always recognize that the decision to conduct the trial in only black patients reflected careful analyses of 2 previous trials in racially mixed patient populations that compared hydralazine hydrochloride-isosorbide dinitrate with placebo or with enalapril. Both trials showed little or no overall effect of hydralazine hydrochloride-isosorbide dinitrate in the mostly white patient population but hinted at a substantial effect in subsets of black patients. Perhaps most critically, the criticisms do not appreciate the urgency of strong scientific evidence of a substantial survival benefit in black patients. A serious attempt to avoid race-based approval by mandating study of a mixed population to identify a possible white patient-responder subset, particularly without a plausible hypothesis as to what that subset might be, would have required years of work, many thousands of patients, and wholly unreasonable delay in approval of a treatment whose effectiveness had been well-documented in the group for which it was intended.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The effect of digoxin on mortality and morbidity in patients with heart failure
(1997) · New England Journal of Medicine · doi:10.1056/nejm199702203360801 · Cited by 3,016
Cohn, J. N., Johnson, G., Ziesche, S., Cobb, F., Francis, G., Tristani, F., Smith, R., Dunkman, W. B., Loeb, H., Wong, M., et al. (1991) · New England Journal of Medicine · doi:10.1056/nejm199108013250502 · Cited by 2,833 · cited 1×
“The first trial (V-HeFT I [8]) compared hydralazine hydrochloride–isosorbide dinitrate with placebo (and prazosin, not further discussed), while the second trial (V-HeFT II [9]) compared hydralazine hydrochloride–isosorbide dinitrate with enalapril, which was by then an established heart failure treatment.”
ResultEffect of Vasodilator Therapy on Mortality in Chronic Congestive Heart Failure
Cohn, J. N., Archibald, D. G., Ziesche, S., Franciosa, J. A., Harston, W. E., Tristani, F. E., Dunkman, W. B., Jacobs, W., Francis, G. S., Flohr, K. H., et al. (1986) · New England Journal of Medicine · doi:10.1056/nejm198606123142404 · Cited by 2,400
Combination of Isosorbide Dinitrate and Hydralazine in Blacks with Heart Failure
Taylor, A. L., Ziesche, S., Yancy, C., Carson, P., D'Agostino, R., Ferdinand, K., Taylor, M., Adams, K., Sabolinski, M., Worcel, M., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa042934 · Cited by 1,773 · cited 1×
“The principal trial of BiDil was the African American Heart Failure Trial (A-HeFT) (7), a randomized comparison of hydralazine hydrochloride–isosorbide dinitrate and placebo in self-identified black patients with New York Heart Association (NYHA) class III or IV (mostly III) heart failure.”
BackgroundYusuf, S. (1991) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1991.03470010097038 · Cited by 1,014 · cited 1×
“Finally, despite legitimate concerns about overinterpreting subset analyses (25), published reports of outcome studies in recent years almost always show forest plots of effects in a wide variety of subsets, invariably including demographic subsets (such as sex, age, and race) and other subsets (for example, disease s…”
BackgroundTemple, R., & Ellenberg, S. S. (2000) · Annals of Internal Medicine · doi:10.7326/0003-4819-133-6-200009190-00014 · Cited by 871
Self-citationBrown, N. J., Ray, W. A., Snowden, M., & Griffin, M. R. (1996) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(96)90161-7 · Cited by 313 · cited 1×
“Differences in drug response by sex (for example, women’s greater susceptibility to torsade de pointes), race (for example, reduced blood pressure response to ACE inhibitors and angiotensin II antagonists and greater susceptibility to ACE inhibitor–induced angioedema in black people [28]), and age (too many to count)…”
BackgroundBloche, M. G. (2004) · New England Journal of Medicine · doi:10.1056/nejmp048271 · Cited by 150
Cited by
Mersha, T. B., & Abebe, T. (2015) · Human Genomics · doi:10.1186/s40246-014-0023-x · Cited by 450
Patient phenotyping in clinical trials of chronic pain treatments: IMMPACT recommendations
Edwards, R. R., Dworkin, R. H., Turk, D. C., Angst, M. S., Dionne, R., Freeman, R., Hansson, P., Haroutounian, S., Arendt-Nielsen, L., Attal, N., et al. (2016) · Pain · doi:10.1097/j.pain.0000000000000602 · Cited by 403
Gill, P. S., Calvert, M., Davis, R., Davies, M. K., Freemantle, N., & Lip, G. Y. H. (2011) · PLoS ONE · doi:10.1371/journal.pone.0026710 · Cited by 43
“[14,15,16] Further a large primary care based study in the UK, the Echocardiographic Heart of England Screening (ECHOES) study, reported that the prevalence of symptomatic left ventricular systolic dysfunction (LVSD) in a predominantly White population aged 45 and older was 0.”
BackgroundMixed Race: Understanding Difference in the Genome Era
Phillips, E. M., Odunlami, A. O., & Bonham, V. L. (2007) · Social Forces · doi:10.1093/sf/86.2.795 · Cited by 24
Metadata
- Authors
- Temple, R., & Stockbridge, N. L.
- Venue
- Annals of Internal Medicine
- Publisher
- American College of Physicians
- Published
- 2007-01-02
- Volume
- 146
- Issue
- 1
- Pages
- 57-62
- ISSN
- 0003-4819 (ISSN-L)
- 1539-3704
- OpenAlex
- W2144054289
- Cited by
- 109
- References
- 8
- FWCI
- 6.70
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: BiDil for Heart Failure in Black Patients: The U.S. Food and Drug Administration Perspective. https://app.cochat.ai/papers/10.7326/0003-4819-146-1-200701020-00010
- The paper
- Temple, R., & Stockbridge, N. L. (2007). BiDil for Heart Failure in Black Patients: The U.S. Food and Drug Administration Perspective. Annals of Internal Medicine. https://doi.org/10.7326/0003-4819-146-1-200701020-00010
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.